SciSparc (NASDAQ:SPRC) Stock Price Down 14.5% – Time to Sell?

SciSparc Ltd. (NASDAQ:SPRC) shares traded down 14.5% during trading on Wednesday. The stock traded as low as $0.5068 and last traded at $0.5126. Approximately 226,750 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 4,215,168 shares. The stock had previously closed at $0.5994.

Analyst Ratings Changes

A number of brokerages recently commented on SPRC. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SciSparc in a research report on Friday, August 21st. Wall Street Zen upgraded SciSparc to a “hold” rating in a report on Saturday, July 18th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company currently has an average rating of “Sell”.

SciSparc Stock Down 2.4%

The business’s 50 day simple moving average is $3.55 and its two-hundred day simple moving average is $5.38.

SciSparc (NASDAQ:SPRC) last posted its earnings results on Friday, August 14th. The company reported ($4.85) EPS for the quarter. The firm had revenue of $0.14 million for the quarter.

About SciSparc

SciSparc Ltd. (NASDAQ: SPRC) is an Israel-based clinical-stage specialty pharmaceutical company focused on developing therapies based on cannabinoid molecules. The company’s research is aimed primarily at central nervous system disorders and other conditions for which existing treatment options may be limited.

SciSparc’s pipeline has included investigational products such as SCI-110, a cannabinoid-based combination therapy being studied for conditions including Tourette syndrome and obstructive sleep apnea, as well as programs addressing Alzheimer’s disease agitation and pain.